SOUTH SAN FRANCISCO, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage
pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor
immunology targets for the treatment of cancer, today announced its participation at the Cowen and Company 37th Annual Health Care
Conference 2017. Susan M. Molineaux, Ph.D., the company’s Founder, President and Chief Executive Officer, will present on
Wednesday, March 8, 2017, at 10:00 a.m. Eastern Time in Boston, Massachusetts. The presentation will be webcast live and available
for replay for up to 30 days at www.calithera.com in the Investor Relations section.
About Calithera
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule
drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product
candidate, CB-839, is a potent, selective, reversible and orally bioavailable inhibitor of glutaminase. CB-839 takes advantage of
the pronounced dependency many cancers have on the nutrient glutamine for growth and survival. It is currently being evaluated in
Phase 1/2 clinical trials in combination with standard of care agents. CB-1158 is a first-in-class immuno-oncology metabolic
checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived
suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the
body’s cancer-fighting immune cells, known as cytotoxic T-cells. CB-1158 is currently in a Phase I clinical trial.
Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate,"
"estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events,
conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to
the Company’s clinical pipeline of novel cancer therapies. Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or implied by such forward-looking statements. The potential
product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals
within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product
characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or
successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a
negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting
Calithera's business can be found in Calithera's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange
Commission, and other periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements
are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims
any obligation to update these forward-looking statements to reflect future events or circumstances.
Contact: Jennifer McNealey ir@Calithera.com 650-870-1071
